BioPharma Resources

Drug Trial Radar · NCT07416604

A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A

A Multicenter, Randomized, Open-Label, Phase III Clinical Trial to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of NXT007 Prophylaxis Versus Emicizumab Prophylaxis in People With Hemophilia A

Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 360 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

360

Planned (sponsor's estimate)

Start

Apr 27, 2026

Primary completion

Feb 29, 2028

Study completion Jan 29, 2032

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
Collaborators
Chugai Pharmaceutical
First posted
Feb 18, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of NXT007 prophylaxis compared with emicizumab prophylaxis in people age 12 years and older with severe or moderate congenital hemophilia A without factor VIII (FVIII) inhibitors or with hemophilia A of any severity (severe, moderate, and mild) with FVIII inhibitors.

Conditions

  • Hemophilia A

Interventions

  • NXT007Combination product

    NXT007 will be administered subcutaneously (SC) using an integrated drug-device combination product.

  • EmicizumabDrug

    Emicizumab will be administered subcutaneously (SC) using vial and syringe.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annualized Bleed Rate (ABR) for Treated Bleeds Over the Main Study Treatment PeriodTime frame: From Month 2 until the clinical cutoff date (at least 7 months of study treatment)

Locations

63 sites in 22 countries. Site status is shown where the registry gives one.

  • Center for Inherited Blood Disorders

    Orange, California · Recruiting

  • University of Colorado Hemophilia and Thrombosis Center

    Aurora, Colorado · Recruiting

  • University Of Miami Hospital

    Miami, Florida · Recruiting

  • St Joseph's Children's Hospital of Tampa

    Tampa, Florida · Recruiting

  • Innovative Hematology, Inc.

    Indianapolis, Indiana · Recruiting

  • University Of Iowa Hospitals And Clinics

    Iowa City, Iowa · Recruiting

  • University of Michigan - 1500 E Medical Center Dr

    Ann Arbor, Michigan · Recruiting

  • M Health Fairview - Pediatric Specialty Clinic-Discovery

    Minneapolis, Minnesota · Recruiting

  • The University of Texas Health Science Center at San Antonio

    San Antonio, Texas · Recruiting

  • Washington Center for Bleeding Disorders

    Seattle, Washington · Recruiting

  • Arbesu Hematologia

    Godoy Cruz, Mendoza Province, Argentina · Recruiting

  • Instituto de Hematología Y Medicina Clínica Dr. Rubén Dávoli

    Rosario, Santa Fe Province, Argentina · Recruiting

  • Royal Prince Alfred Hospital

    Camperdown, New South Wales, Australia · Recruiting

  • The Alfred Hospital

    Melbourne, Victoria, Australia · Recruiting

  • Royal Children's Hospital Melbourne - PIN

    Parkville, Victoria, Australia · Recruiting

  • Cliniques Universitaires Saint-Luc

    Brussels, Belgium · Recruiting

  • UZ Leuven

    Leuven, Antwerp, Belgium · Recruiting

  • Hemocentro Da UNICAMP

    São Paulo, Brazil · Recruiting

  • Hospital Das Clinicas da Faculdade de Medicina de Ribeirão Preto - USP

    Ribeirão Preto, São Paulo, Brazil · Recruiting

  • London Health Sciences Centre

    London, Ontario, Canada · Recruiting

  • Peking Union Medical College Hospital - East Campus

    Beijing, Beijing Municipality, China · Recruiting

  • Fujian Medical University Union Hospital

    Fuzhou, Fujian, China · Recruiting

  • Nanfang Hospital, Southern Medical University

    Guangzhou, Guangdong, China · Recruiting

  • Chengdu Women's and Children's Central Hospital

    Chengdu, Sichuan, China · Recruiting

  • Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences

    Tianjin, Tianjin Municipality, China · Recruiting

  • Rigshospitalet

    København Ø, Capital, Denmark · Recruiting

  • Hospices Civils de Lyon

    Bron, France · Recruiting

  • CHU de Lille - Institut Cœur Poumon

    Lille, France · Recruiting

  • AP-HP - Hôpital universitaire Necker-Enfants malades

    Paris, France · Recruiting

  • AP-HP - Hôpital Bicêtre

    Le Kremlin-Bicêtre, Val-de-Marne, France · Recruiting

  • Universitätsklinikum Hamburg-Eppendorf

    Hamburg, Germany · Recruiting

  • Universitätsklinikum Bonn

    Bonn, North Rhine-Westphalia, Germany · Recruiting

  • Debreceni Egyetem Klinikai Kozpont Nagyerdei Campus

    Debrecen, Pest County, Hungary · Recruiting

  • St James's Hospital

    Dublin, Ireland · Recruiting

  • Children?s Health Ireland at Crumlin

    Dublin, Ireland · Recruiting

  • The Chaim Sheba Medical Center - PPDS

    Ramat Gan, Central District, Israel · Recruiting

  • Azienda Ospedaliera Universitaria Federico II

    Naples, Campania, Italy · Recruiting

  • Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico

    Milan, Lombardy, Italy · Recruiting

  • IRCCS Istituto Clinico Humanitas

    Rozzano, Lombardy, Italy · Recruiting

  • Azienda Ospedaliera Universitaria Careggi

    Florence, Tuscany, Italy · Recruiting

Showing 40 of 63 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.